Results 131 to 140 of about 591 (191)

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors. [PDF]

open access: yesFuture Oncol
Powles T   +21 more
europepmc   +1 more source

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. [PDF]

open access: yesClin Cancer Res
Ku G   +27 more
europepmc   +1 more source

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. [PDF]

open access: yesJ Immunother Cancer
Rohrberg KS   +38 more
europepmc   +1 more source

A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors. [PDF]

open access: yesFront Oncol
Gill D   +21 more
europepmc   +1 more source

605 Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)

open access: yesJournal for ImmunoTherapy of Cancer
Drew Rasco   +17 more
doaj   +1 more source

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). [PDF]

open access: yesJ Immunother Cancer
Davar D   +19 more
europepmc   +1 more source

611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study

open access: yesJournal for ImmunoTherapy of Cancer
Andrew Haydon   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy